Amgen strikes outcomes-based payment plan for Enbrel with AbarcaPharmacy benefit manager Abarca has announced a US reimbursement contract with Amgen for its Enbrel (etanercept) inflammatory diseases Share XAmgen strikes outcomes-based payment plan for Enbrel with Abarcahttps://pharmaphorum.com/news/amgen-strikes-outcomes-based-payment-plan-for-enbrel-with-abarca/
Roche backs Rituxan with further data in rare skin disease PVRoche’s Rituxan (rituximab) has been on the market for years as a blood cancer drug, and is finally Share XRoche backs Rituxan with further data in rare skin disease PVhttps://pharmaphorum.com/news/roche-backs-rituxan-with-further-data-in-rare-skin-disease-pv/
Roche’s Gazyva wins Breakthrough Therapy status for lupus nephritisRoche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, Share XRoche’s Gazyva wins Breakthrough Therapy status for lupus nephritishttps://pharmaphorum.com/news/roches-gazyva-wins-breakthrough-therapy-status-for-lupus-nephritis/
Novartis’ Cosentyx heads for fourth indicationNovartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it Share XNovartis’ Cosentyx heads for fourth indicationhttps://pharmaphorum.com/news/cosentyx-heads-for/
Could phase 3 trial win save AZ’s troubled Lupus drug?AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a Share XCould phase 3 trial win save AZ’s troubled Lupus drug?https://pharmaphorum.com/news/could-phase-3-trial-win-save-azs-troubled-lupus-drug/
Three years after approval, court blocks US launch of Enbrel biosimilarSandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel Share XThree years after approval, court blocks US launch of Enbrel biosimilarhttps://pharmaphorum.com/news/three-years-after-approval-court-blocks-us-launch-of-enbrel-biosimilar/
Gilead invests $5.1bn in Belgian biotech GalapagosBelgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis Share XGilead invests $5.1bn in Belgian biotech Galapagoshttps://pharmaphorum.com/news/gilead-invests-5-1bn-in-belgian-biotech-galapagos/
EU regulators slap safety restriction on Pfizer’s XeljanzEuropean safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher Share XEU regulators slap safety restriction on Pfizer’s Xeljanzhttps://pharmaphorum.com/news/eu-regulators-slap-safety-restriction-on-pfizers-xeljanz/
J&J unveils top pipeline prospects, with main focus on cancerJohnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans Share XJ&J unveils top pipeline prospects, with main focus on cancerhttps://pharmaphorum.com/news/jj-unveils-top-pipeline-prospects-cancer/
